Skip to main content

Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador



Carbapenem-resistant gram-negative bacilli are a worldwide concern because of high morbidity and mortality rates. Additionally, the increasing prevalence of these bacteria is dangerous. To investigate the extent of antimicrobial resistance and prioritize the utility of novel drugs, we evaluated the molecular characteristics and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Ecuador in 2022.


Ninety-five clinical isolates of carbapenem non-susceptible gram-negative bacilli were collected from six hospitals in Ecuador. Carbapenem resistance was confirmed with meropenem disk diffusion assays following Clinical Laboratory Standard Institute guidelines. Carbapenemase production was tested using a modified carbapenemase inactivation method. Antimicrobial susceptibility was tested with a disk diffusion assay, the Vitek 2 System, and gradient diffusion strips. Broth microdilution assays were used to assess colistin susceptibility. All the isolates were screened for the blaKPC, blaNDM, blaOXA-48, blaVIM and blaIMP genes. In addition, A. baumannii isolates were screened for the blaOXA-23, blaOXA-58 and blaOXA-24/40 genes.


Carbapenemase production was observed in 96.84% of the isolates. The blaKPC, blaNDM and blaOXA-48 genes were detected in Enterobacterales, with blaKPC being predominant. The blaVIM gene was detected in P. aeruginosa, and blaOXA-24/40 predominated in A. baumannii. Most of the isolates showed co-resistance to aminoglycosides, fluoroquinolones, and trimethoprim/sulfamethoxazole. Both ceftazidime/avibactam and meropenem/vaborbactam were active against carbapenem-resistant gram-negative bacilli that produce serin-carbapenemases.


The epidemiology of carbapenem resistance in Ecuador is dominated by carbapenemase-producing K. pneumoniae harbouring blaKPC. Extensively drug resistant (XDR) P. aeruginosa and A. baumannii were identified, and their identification revealed the urgent need to implement strategies to reduce the dissemination of these strains.

Peer Review reports


The increasing number of multidrug-resistant organisms (MDROs) constitutes a major threat to health worldwide. MDROs are linked to increasing costs and mortality rates [1] and are an important challenge to clinicians due to the complicated choice of treatment option [2].

The World Health Organization included carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales as “priority antibiotic-resistant pathogens”, for which the research and development of new antimicrobial agents is critical [3]. The dissemination of these pathogens is mainly due to high-risk clones and is generally associated with health care-associated infections with high mortality rates [4, 5].

The mechanisms of carbapenem resistance are diverse but are dominated by the expression of carbapenemases. The prevalence of carbapenemases varies according to region [2]. In Ecuador, despite the high prevalence of carbapenem-resistant Enterobacterales (CRE) (37%) and other gram-negative rod-shaped bacteria [6, 7], there is little information about the mechanisms involved and the antimicrobial susceptibility profiles, including that to recently approved antibiotics such as ceftazidime/avibactam, meropenem/vaborbactam, or ceftolozane/tazobactam, which constitute the first line of treatment against carbapenem-resistant gram-negative rod-shaped bacteria [8, 9].

Thus, essential information is required to optimize the administration of antibiotics as a lack of knowledge could lead to the misuse of antibiotics and the rapid development of antimicrobial resistance.

Therefore, to clarify the extent of antimicrobial resistance and prioritize the utility of newly available drugs, our goal was to determine the molecular characteristics and antimicrobial susceptibility profiles of clinical CRE, P. aeruginosa and A. baumannii complex isolates from Ecuador.


A multicentre study was carried out in six hospitals in Ecuador between January 2022 and May 2022. Clinical isolates of CRE, P. aeruginosa and the A. baumannii complex were collected according to protocols established by each institution. Carbapenem resistance was defined when the isolate was non-susceptible to any of the carbapenems tested according to Clinical Standards Institute (CLSI) breakpoints [10]. Only one clinical isolate from each patient was studied, and there was a preference for samples from sterile sites or those with the greatest resistance phenotype.

CRE isolates were cultured on CHROMagar Super Carba (CHROMagar, France). P. aeruginosa and A. baumannii complex isolates were cultured on MacConkey agar (16–18 h; 35 °C) (Becton–Dickinson, England) to check their viability and purity. Isolates were identified with the Vitek 2 System (BioMérieux, France) and conventional biochemical tests.

Carbapenem resistance was confirmed with meropenem disk diffusion assays using CLSI methodology. Carbapenemase production was studied with the modified carbapenem inactivation method (mCIM) for Enterobacterales and P. aeruginosa according to CLSI guidelines [10]. A. baumannii complex isolates were studied with the optimized carbapenem inactivation method described by Zhang S. et al. [11].

Antimicrobial susceptibility testing

Susceptibility tests for ciprofloxacin, amikacin, gentamicin, trimethoprim/sulfamethoxazole, tigecycline, ceftazidime, cefepime, meropenem imipenem, ampicillin/sulbactam and piperacillin/tazobactam were performed using disk diffusion assays and the Vitek 2 System (AST-N402 or AST-N401 Card) (BioMérieux, France). Minimal inhibitory concentrations (MICs) for ceftazidime/avibactam and meropenem/vaborbactam were determined using gradient diffusion strips (Liofilchem, Italy). MIC values and disk diffusion results were interpreted using CLSI breakpoints [10]. For tigecycline, the U.S. Food and Drug Administration (FDA) breakpoints were used (susceptible ≥ 19 mm or ≤ 2 µg/ml) for Enterobacterales [12]. For meropenem/vaborvactam, European Committee on Antimicrobial Susceptibility (EUCAST) testing breakpoints were used for P. aeruginosa (susceptible ≤ 8 µg/ml) [13].

Susceptibility to ceftazidime/avibactam and meropenem/vaborbactam was not tested in NDM-positive isolates.

The MIC of colistin was obtained using a broth microdilution (CBM) method, as described in CLSI document M07-A8 [14]. Analytical grade colistin sulfate (Sigma‒Aldrich Code C2700000, batch 3.0) and Mueller Hinton broth with cation adjustment (Thermo Fischer Scientific, United Kingdom) were used. The concentration range was 0.5–4 µg/mL, and CLSI breakpoints were used to define colistin resistance (MIC values ≥ 4 µg/mL) [10]. The MIC50 and MIC90 were determined for each antimicrobial.

Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853, K. pneumoniae BAA ATCC 1705 and E. coli AR Bank #0349 were used for quality control.

Detection of carbapenemase and mcr-1 genes

The carbapenemase-encoding genes blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP were studied using multiplex polymerase chain reaction (PCR) in all isolates [15]. Additionally, the blaOXA-23-like, blaOXA-58 and blaOXA-24/40-like genes were studied in A. baumannii complex isolates with a previously described multiplex PCR method [16].

The molecular detection of the colistin-resistance gene mcr-1 was performed via PCR [17].

Clonality study

Clonal relatedness was studied in blaKPC-positive K. pneumoniae, blaVIM-positive P. aeruginosa and blaOXA-24/40-positive A. baumannii complex using ERIC-PCR following a previously described method [18].

Dendrograms were constructed using GelJ software based on Dice’s similarity coefficient and the unweighted pair group method (UPGM) (tolerance 2%). The cut-off level for ERIC-PCR electrophoretic pattern delineation was 80% similarity.


One hundred and twenty-nine isolates were obtained for analysis. Thirty-four were rejected for inconsistencies in shipments or duplications (26.35%). Thus, a total of ninety-five isolates were included in the study (73.64%).

Enterobacterales predominated among the sample and accounted for 60 isolates studied (63.15%), with K. pneumoniae being the most frequently isolated species (n = 45; 47.36%). K. aerogenes, E. cloacae and E. coli were also present in 16.66% (n = 10), 5% (n = 3) and 3.33% (n = 2) of samples, respectively. The A. baumannii complex was present in 25.26% (n = 24) of the samples, and P. aeruginosa was present in 11.57% (n = 11) of the samples.

Carbapenemase production was confirmed in 92 isolates (96.84%). Three P. aeruginosa isolates tested negative for mCIM.

BlaKPC was the most frequent carbapenemase-encoding gene found in Enterobacterales (n = 52; 86.66%). BlaNDM (n = 7; 11.66%) and blaOXA-48 (n = 1; 1.66%) were also detected. Neither blaIMP nor blaVIM was detected in Enterobacterales. Both ceftazidime/avibactam (MIC50 and MIC90 <  = 0.12/4 µg/ml) and meropenem/vaborbactam (MIC50 0.064/8 µg/ml; MIC90 0.84/8 µg/ml) were active against all tested isolates harbouring blaKPC. The susceptibility rates to CPE were 95% and 76.67% for tigecycline and colistin, respectively.

Detailed information about the susceptibility patterns of the CPE strains, K. pneumoniae strains and K. aerogenes blaKPC strains is provided in Table 1.

Table 1 Antimicrobial susceptibility against carbapenemase-producing Enterobacterales

Tigecycline and colistin were the only drugs that K. aerogenes blaNDM isolates were susceptible to (n = 1). E. cloacae blaKPC isolates (n = 2) were resistant to most of the antimicrobials tested, except for amikacin tigecycline, colistin, ceftazidime/avibactam and meropenem/vaborbactam, as observed for E. coli blaKPC (n = 1).

E. cloacae blaNDM (n = 1) was only susceptible to colistin and amikacin.

The susceptibility profile of E. coli blaoxa-48 was the most conserved. This isolate was resistant to only ciprofloxacin, trimethoprim/sulfamethoxazole, and ceftazidime. Tigecycline, colistin, ceftazidime/avibactam, trimethoprim/sulfamethoxazole and colistin were active against E. coli blaKPC. These strains were resistant to ciprofloxacin, aminoglycosides and all beta-lactam antimicrobial agents tested.

In P. aeruginosa, only blaVIM was detected (n = 8; 72.72%). Three isolates lacked any of the examined carbapenemase genes and tested negative for mCIM. All antimicrobials tested showed high resistance in blaVIM-positive P. aeruginosa. Ceftolozane/tazobactam was active against carbapenemase-negative P. aeruginosa.

In A. baumannii complex isolates, 66.66% (n = 16) of the patients were blaOXA-24/40 positive, and 33.33% (n = 8) of the patients were blaOXA23 positive. blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP were not detected in any of the isolates. A. baumannii complex isolates were only susceptible to colistin (95%), regardless of which gene was present in the isolates.

Tables 2 and 3 provide comprehensive details regarding carbapenem-resistant non-fermentative gram-negative pathogens. The MIC values of the antimicrobials evaluated are detailed in Supplementary Table 1.

Table 2 Susceptibility antimicrobial against P. aeruginosa
Table 3 Susceptibility antimicrobial against A. baumannii complex

None of the colistin-resistant isolates carried the mcr-1 gene.

BlaVIM-positive P. aeruginosa and blaKPC-positive K. pneumoniae (n = 35) isolates exhibited significant genetic heterogenicity (Supplementary Figs. 1 and 2).

In the blaOXA-24/40-positive A. baumannii complex, six electrophoretic patterns were found, and 50% of the isolates belonged to only one pattern, indicating the clonal dissemination of this microorganism (Supplementary Fig. 3).

Four electrophoretic patterns were found in blaKPC-positive K. aerogenes (8 isolates studied) (Supplementary Fig. 4).


Our research describes the molecular characteristics of carbapenem-resistant gram-negative rod-shaped bacteria in Ecuador. Carbapenemase production was prevalent in the isolates studied (96.64%), and carbapenemase production has been described by several authors as the main mechanism involved in carbapenem resistance [6, 19,20,21].

Carbapenemase-encoding genes such as blaKPC, blaNDM and blaOXA-48 were detected in Enterobacterales, and blaKPC was the predominant gene. Our results are similar to those described in other Western countries, such as the United States, Argentina, Colombia, and Brazil, which described blaKPC as the prevalent gene linked to K. pneumoniae [7, 21, 22]. Our results also agree with previous data published in 2022 by the National Reference Laboratory, which described K. pneumoniae harbouring blaKPC as the main cause of carbapenem resistance in Enterobacterales in Ecuador [23].

In our study, we did not find blaNDM (11.47%) or blaOXA-48 (1.64%) genes very frequently in Enterobacterales; these percentages are comparable to those reported in a national surveillance report [23]. However, given the small number of isolates, we advise using caution when considering this information. BlaNDM was detected in K. pneumoniae, K. aerogenes and E. cloacae. Interestingly, we did not find any P. rettgeri isolates harbouring this gene because this species has been shown to play a central role in the dissemination of blaNDM in Latin America, but infections by P. rettgeri are not very common [24]. Similar to other studies, we found blaOXA-48 only in E. coli, which is the main species associated with this gene [25, 26].

The pattern observed in Ecuador is different from that described in other countries, such as India, where NDM is prevalent, or Turkey, where OXA-48 dominates among CRE [26, 27].

During the COVID-19 pandemic, an increase in carbapenemase-producing Enterobacterales was observed; moreover, the emergence of isolates harbouring more than one carbapenemase gene was reported [28]. In 2021, Ecuador reported blaKPC + blaNDM and blaKPC + blaOXA-48 associations [28, 29]. Nevertheless, we did not find any combinations of carbapenemase genes in any of the isolates studied.

Co-resistance to aminoglycosides and fluoroquinolones was observed in K. pneumoniae blaKPC-positive isolates. This association has also been described by several authors and is linked to horizontal dissemination [30, 31]. Genetic diversity was revealed in our isolates, suggesting horizontal dissemination. Interestingly, our results differ from those of previous research in which clonal circulation of K. pneumoniae blaKPC-positive isolates was documented [18]. The differences found could be attributed to the fact that our study was not limited to one city or hospital area, such as intensive care units, where most other research is focused.

According to our results, tigecycline could be considered a therapeutic alternative for Enterobacterales isolates, independent of carbapenemase genes or the species involved, but its use will require a previous antimicrobial susceptibility report, as other authors have also suggested [32].

Enterobacterales harbouring blaKPC showed reduced susceptibility to colistin, but surprisingly, all isolates harbouring blaNDM remained susceptible to colistin, contrary to the findings of other authors, who described an increase in colistin resistance in CRE isolates harbouring blaNDM [33]. Based on our findings, colistin may be considered a significant therapeutic option for the treatment of CRE, but a prior susceptibility report may be needed. The mcr-1 gene was not detected in any of our isolates, in contrast with the results of other Latin American studies [34,35,36], suggesting that resistance could be mediated by chromosomal mutations or other mcr variants that were not studied and have been described in the region, including mcr-3 or mcr-5 [37,38,39]. Further studies are needed to understand the resistance mechanisms involved in colistin resistance.

New antimicrobial agents, such as ceftazidime/avibactam and meropenem/vaborbactam, demonstrated complete susceptibility in all the blaKPC-positive isolates. Despite the susceptibility patterns reported by several authors, the emergence of KPC isolates with ceftazidime/avibactam resistance has been reported, which has been frequently associated with mutations leading to substitutions in the Ω-loop of the KPC-3 variant [40, 41]. Fortunately, our research did not show any resistance to this new antimicrobial in KPC isolates, perhaps due to the recent introduction of this antimicrobial (June 2022) in Ecuador, although some cases of CAZ/AVI resistance have been reported prior to drug introduction in other countries through a salt bridge between glutamic 197 and arginine 164 in the wild-type KPC enzyme; however, this result was not found in this study [42].

Carbapenemase production by the blaVIM gene was detected in 63.63% of P. aeruginosa isolates, and this gene encodes a metallo-β-lactamase. Our findings are consistent with several other authors who determined that this gene was prevalent [43]. P. aeruginosa exhibited high rates of co-resistance to aminoglycosides, ciprofloxacin, colistin and ceftolozane/tazobactam, rendering these antimicrobials ineffective for empirical treatment. Our findings differ from those of other authors who recommended ceftolozane/tazobactam as an effective treatment for multidrug-resistant P. aeruginosa [44]. In contrast to our findings, Ajila et al. reported good susceptibility to ceftolozane/tazobactam in P. aeruginosa isolates recovered in 2019 in Ecuador [45]. We attributed these conflicting findings to the molecular mechanisms involved in the studied isolates, but these hypotheses were not described by the authors.

In America, carbapenem resistance in A. baumannii complex isolates is principally mediated by oxacillinases, particularly blaOXA-23 and blaOXA-58 [46, 47]. In 2016, Nuñez-Quezada et al. reported an outbreak of a carbapenem-resistant A. baumannii complex with blaOXA-72, a member of the blaOXA-24/40 subgroup, in Guayaquil, Ecuador [48]. Our research revealed that blaOXA-24/40 (66.66%) was predominant in A. baumannii complex isolates, similar to the results of a previous report in our country; furthermore, the same PCR pattern was observed in 50% of the isolates, which indicates the clonal spread of this microorganism, as has been previously reported [48].

Nevertheless, our results differ from those published in a national surveillance report, which showed a predominance of OXA-23 in A. baumannii complex isolates collected from 2019 to 2021. However, an increase in OXA-24/40 was observed in 2021, with similar values to those of OXA-23 (blaOXA-23 n = 129; blaOXA-24/40 n = 116). In addition, we did not detect blaOXA-58 in our isolates, although it has been reported previously in Ecuador [23]. Our results also differ from the regional epidemiology [49], where the blaOXA-24/40 gene has been described only sporadically and is mainly reported in countries such as Taiwan, China and South Korea in Asia [50, 51].

Co-resistance to other groups of drugs is highly common in A. baumannii complex isolates, and this co-resistance reduces the number of therapeutic options. The extensive drug resistance (XDR) phenotype was independent of the oxacillinase gene. The isolates only showed 100% susceptibility to colistin, and colistin could be considered a last resort option for these XDR isolates.

This study has several limitations. First, our results could not be generalized to primary care hospitals or other cities as the hospitals were not randomly selected; instead, they included hospitals from public and private services from the second and third levels of attention in Ecuador´s most populous cities. Second, clinical isolates of carbapenem-resistant gram-negative bacilli were selected by each microbiology laboratory according to their protocols and clinical requests for culture by physicians; therefore, some isolates were not included. Third, the sensitivity and specificity of the mCIM method are greater than 90%, although there could be false-negative results due to uncommon carbapenemase types that were not tested in our study [52]. Finally, blaOXA143, which is an oxacillinase previously described in A. baumannii in Ecuador, has not been examined.

In conclusion, the epidemiology of carbapenem resistance in the three most important cities of Ecuador (Quito, Guayaquil, and Cuenca) was dominated by carbapenemase-producing K. pneumoniae harbouring blaKPC. Additionally, XDR P. aeruginosa and A. baumannii complex isolates were also present, showing an urgent need to implement strategies to reduce their dissemination.

Availability of data and materials

The datasets used during the current study are available from the corresponding author upon reasonable request.


  1. Knols BG, Smallegange RC, Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Lancet Infect Dis. 2009;9(9):535–6.

    Article  Google Scholar 

  2. Pournaras S, Zarrilli R, Higgins PG, Tsioutis C. Editorial: carbapenemase-producing organisms as leading cause of hospital infections. Front Med. 2021;8:10–2.

    Article  Google Scholar 

  3. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available from: [cited 2023 Aug 21].

  4. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62(5):895–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ko KS. Antibiotic-resistant clones in Gram-negative pathogens: presence of global clones in Korea. J Microbiol. 2019;57(3):195–202.

    Article  CAS  PubMed  Google Scholar 

  6. Sánchez-López J, Cantón R. Current status of ESKAPE microorganisms in Spain: epidemiology and resistance phenotypes. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter. 2019;32:27–31.

    Google Scholar 

  7. García-Betancur JC, Appel TM, Esparza G, Gales AC, Levy-Hara G, Cornistein W, et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2021;19(2):197–213.

    Article  PubMed  Google Scholar 

  8. Tamma PD, Hsu AJ. Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms. J Pediatr Infect Dis Soc. 2019;8(3):251–60.

    Article  Google Scholar 

  9. Doi Y. Treatment options for Carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 31th informational supplement. CLSI document M100-S31. Wayne: Clinical and Laboratory Standars Institute - NCCLS; 2021.

    Google Scholar 

  11. Zhang S, Mi P, Wang J, Li P, Luo K, Liu S, et al. The optimized carbapenem inactivation method for objective and accurate detection of carbapenemase-producing Acinetobacter baumannii. Front Microbiol. 2023;14:1–13.

    Google Scholar 

  12. Food and Drug Aministration C for DE and FDA. FDA. Tigecycline – Injection products. 2023. Available from: [cited 2024 Jan 30].

  13. European Committee on Anitmicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024–01–01. Available from: [cited 2024 Jan 30].

  14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard — Ninth Edition. Vol. 32, methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- Ninth Edition. 2012. p. 18.

  15. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–23.

    Article  CAS  PubMed  Google Scholar 

  16. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27(4):351–3.

    Article  CAS  PubMed  Google Scholar 

  17. Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Eurosurveillance. 2018;23(6):1–11.

    Article  Google Scholar 

  18. Soria-Segarra C, Soria-Segarra C, Catagua-González A, Gutiérrez-Fernández J. Carbapenemase producing Enterobacteriaceae in intensive care units in Ecuador: results from a multicenter study. J Infect Public Health. 2020;13(1):80–8.

    Article  PubMed  Google Scholar 

  19. Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo- β -lactamase ( NDM ): a threat to public health. BMC Microbiol. 2017;17:1–12.

    Article  Google Scholar 

  20. Haji SH, Aka STH, Ali FA. Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli. PLoS One. 2021;16:e0259005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2017;15(3):277–97.

    Article  PubMed  Google Scholar 

  22. Hansen GT. Continuous evolution: perspective on the epidemiology of Carbapenemase resistance among enterobacterales and other gram-negative bacteria. Infect Dis Ther. 2021;10(1):75–92.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ecuador IN de I y SP del. Vigilancia de BLEE y Carbapenemasas en Ecuador período 2018–2021. Available from: [cited 2023 Sep 20].

  24. Marquez-Ortiz RA, Haggerty L, Olarte N, Duarte C, Garza-Ramos U, Silva-Sanchez J, et al. Genomic epidemiology of NDM-1-encoding plasmids in latin American clinical isolates reveals insights into the evolution of multidrug resistance. Genome Biol Evol. 2017;9(6):1725–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Findlay J, Perreten V, Poirel L, Nordmann P. Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020. Eur J Clin Microbiol Infect Dis. 2022;41(11):1355–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Neidhöfer C, Buechler C, Neidhöfer G, Bierbaum G, Hannet I, Hoerauf A, et al. Global distribution patterns of Carbapenemase-encoding bacteria in a new light: clues on a role for ethnicity. Front Cell Infect Microbiol. 2021;11:1–9.

    Article  Google Scholar 

  27. van Duin D, Doi Y. The global epidemiology of Carbapenemase-producing enterobacteriaceae. Virulence. 2017;8(4):460–9.

    Article  PubMed  Google Scholar 

  28. Organizacion Panamericana de la Salud. Emergencia e incremento de nuevas combinaciones de carbapenemasas en Enterobacterales en Latinoamérica y el Caribe. 2021. Available from: [cited 2023 Sep 20]. 

  29. Organización Panamericana de la Salud. Emergencia e incremento de nuevas combinaciones de carbapenemasas en Enterobacterales en Latinoamérica y el Caribe. Emerg E Incremento Nuevas Comb Carbapenemasas En Enterobacterales En Latinoam El Caribe. 2021;(Vim):2–8.

  30. Oliveira R, Castro J, Silva S, Oliveira H, Saavedra MJ, Azevedo NF, et al. Exploring the antibiotic resistance profile of clinical Klebsiella pneumoniae Isolates in Portugal. Antibiotics. 2022;11(11):1613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. González Rocha G, Vera Leiva A, Barría Loaiza C, Carrasco Anabalón S, Lima C, Aguayo Reyes A, et al. Infectología al Día KPC: Klebsiella pneumoniae carbapenemasa, principal carbapenemasa en enterobacterias KPC. Infectol Al Día. 2017;34(5):476–84.

    Google Scholar 

  32. Malek A, McGlynn K, Taffner S, Fine L, Tesini B, Wang J, et al. Next-generation-sequencing-based hospital outbreak investigation yields insight into Klebsiella aerogenes population structure and determinants of Carbapenem resistance and pathogenicity. Antimicrob Agents Chemother. 2019;63(6):302577–18.

    Article  Google Scholar 

  33. El-Mahallawy HA, El Swify M, Abdul Hak A, Zafer MM. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae. Ann Med. 2022;54(1):1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Zarate M, Barrantes D, Cuicapuza D, Velasquez J, Fernández N, Salvatierra G, et al. Frequency of colistin resistance in Pseudomonas aeruginosa: first report from Peru. Rev Peru Med Exp Salud Pública. 2021;38:308–12.

    Article  PubMed  Google Scholar 

  35. Garza-Ramos U, Silva-Sánchez J, López-Jácome LE, Hernández-Durán M, Colín-Castro CA, Sánchez-Pérez A, et al. Carbapenemase-encoding genes and colistin resistance in gram-negative bacteria during the COVID-19 pandemic in Mexico: results from the Invifar network. Microb Drug Resist. 2023;29(6):239–48.

    Article  CAS  PubMed  Google Scholar 

  36. Ortega-Paredes D, Barba P, Zurita J. Colistin-resistant Escherichia coli clinical isolate harbouring the mcr-1 gene in Ecuador. Epidemiol Infect. 2016;144(14):2967–70.

    Article  CAS  PubMed  Google Scholar 

  37. Calero-CÃ W. Evolution and dissemination of mobile colistin resistance genes: limitations and challenges in Latin American countries. Lancet. 2023;4:e571.

    Google Scholar 

  38. Mendes Oliveira VR, Paiva MC, Lima WG. Plasmid-mediated colistin resistance in Latin America and Caribbean: a systematic review. Travel Med Infect Dis. 2019;31:101459.

    Article  PubMed  Google Scholar 

  39. Daza-Cardona EA, Buenhombre J, Fontenelle RO dos S, Barbosa FCB. mcr-mediated colistin resistance in South America, a One Health approach: a review. Rev Res Med Microbiol. 2022;33(1):e119.

    Article  Google Scholar 

  40. Findlay J, Poirel L, Juhas M, Nordmann P. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021;65(9):e0089021.

    Article  PubMed  Google Scholar 

  41. Cui X, Shan B, Zhang X, Qu F, Jia W, Huang B, et al. Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae from patients without ceftazidime-avibactam use history – a multicenter study in China. Front Microbiol. 2020;11:1–9.

    Article  Google Scholar 

  42. Wozniak A, Paillavil B, Legarraga P, Zumarán C, Prado S, García P. Evaluation of a rapid immunochromatographic test for detection of KPC in clinical isolates of Enterobacteriaceae and Pseudomonas species. Diagn Microbiol Infect Dis. 2019;95(2):131–3.

    Article  CAS  PubMed  Google Scholar 

  43. Schäfer E, Malecki M, Tellez-Castillo CJ, Pfennigwerth N, Marlinghaus L, Higgins PG, et al. Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany. Antimicrob Resist Infect Control. 2019;8(1):1–7.

    Article  Google Scholar 

  44. Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5(11):ofy280.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ajila Acuña A, Satán Salazar C, Villavicencio F, Villacís JE. Determinación de la actividad de ceftolozane/tazobactam en cepas de. Rev Científica INSPILIP. 2022;6(1):9–18.

  46. Liu C, Chen K, Wu Y, Huang L, Fang Y, Lu J, et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units ( ICUs ) in China. Emerg Microbes Infect. 2022;11(1):1730–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. McKay SL, Vlachos N, Daniels JB, Albrecht VS, Stevens VA, Rasheed JK, et al. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii in the United States, 2013–2017. Microb Drug Resist. 2022;28(6):645–53.

    Article  CAS  PubMed  Google Scholar 

  48. Nuñez Quezada T, Rodríguez CH, Castro Cañarte G, Nastro M, Balderrama Yarhui N, Dabos L, Acosta Mosquera Y, Plaza Moreira N, Famiglietti A. Outbreak of blaOXA-72-producing Acinetobacter baumannii in South America. J Chemother. 2017;29(5):321–4.

  49. Rodríguez CH, Balderrama Yarhui N, Nastro M, Nuñez Quezada T, Castro Cañarte G, Magne Ventura R, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in South America. J Med Microbiol. 2016;65(10):1088–91.

    Article  PubMed  Google Scholar 

  50. Chen Y, Yang Y, Liu L, Qiu G, Han X, Tian S, et al. High prevalence and clonal dissemination of OXA-72-producing Acinetobacter baumannii in a Chinese hospital: a cross sectional study. BMC Infect Dis. 2018;18(1):491.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Thirapanmethee K, Srisiri-a-nun T, Houngsaitong J, Montakantikul P, Khuntayaporn P, Chomnawang MT. xcPrevalence of OXA-Type β-lactamase genes among Carbapenem-resistant acinetobacter baumannii clinical isolates in Thailand. BMC Infect Dis. 2020;9(12):864.

    CAS  Google Scholar 

  52. Gutiérrez S, Correa A, Hernández-Gómez C, De La Cadena E, Pallares C, Villegas MV. Detection of carbapenemase-producing Pseudomonas aeruginosa: evaluation of the carbapenem inactivation method (CIM). Enfermedades Infecc Microbiol Clin Engl Ed. 2019;37(10):648–51.

    Article  Google Scholar 

Download references


Not applicable.


This research was supported by Pfizer grant No 68213903.

Author information

Authors and Affiliations



SSCL, SSC, GFJ contributed to study conception, design, and analysis. SSCL wrote the draft version of the manuscript. MMM, AOI, NQT, CAK, MAM, STM, GHM, VHV, VJE, contributed to collection and data analysis. All authors commented on previous versions of the manuscript. All authors reviewed, revised, and approved the final manuscript.

Corresponding author

Correspondence to Claudia Soria-Segarra.

Ethics declarations

Ethics approval and consent to participate

The study was carried out according to the Declaration of Helsinki and was approved by the “Comite de Etica de Investigación en Seres humanos de la Pontificia Universidad Católica del Ecuador (PUCE) “[EO-26–2021]. Informed consent was waived due to the retrospective design of the study by the Ethical Committee of “Pontificia Universidad Católica del Ecuador (PUCE) (EO-26–20210.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soria-Segarra, C., Soria-Segarra, C., Molina-Matute, M. et al. Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador. BMC Infect Dis 24, 378 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: